O	0	4	Dose
O	5	14	intensity
O	15	17	in
O	18	31	anthracycline
O	31	32	-
O	32	37	based
O	38	50	chemotherapy
O	51	54	for
O	55	65	metastatic
O	66	72	breast
O	73	79	cancer
O	79	80	:
O	81	87	mature
O	88	95	results
O	96	98	of
O	99	102	the
O	103	113	randomised
O	114	122	clinical
O	123	128	trial
O	129	132	ANZ
O	133	137	9311
O	137	138	.

O	139	142	The
O	143	151	separate
O	152	159	impacts
O	160	162	of
O	163	167	dose
O	168	171	and
O	172	176	dose
O	177	186	intensity
O	187	189	of
O	190	202	chemotherapy
O	203	206	for
O	207	217	metastatic
O	218	224	breast
O	225	231	cancer
O	232	238	remain
O	239	248	uncertain
O	248	249	.

O	250	253	The
O	254	261	primary
O	262	271	objective
O	272	274	of
O	275	279	this
O	280	285	trial
O	286	289	was
O	290	292	to
O	293	300	compare
O	301	302	a
O	303	308	short
O	308	309	,
O	310	314	high
O	314	315	-
O	315	319	dose
O	319	320	,
O	321	330	intensive
O	331	337	course
O	338	340	of
O	341	351	epirubicin
O	352	355	and
O	356	372	cyclophosphamide
O	373	374	(
O	374	376	EC
O	376	377	)
O	378	382	with
O	383	384	a
O	385	391	longer
O	392	404	conventional
O	405	409	dose
O	410	417	regimen
O	418	428	delivering
O	429	432	the
O	433	437	same
O	438	443	total
O	444	448	dose
O	449	451	of
O	452	464	chemotherapy
O	464	465	.

O	466	470	This
O	471	475	open
O	476	481	label
O	482	487	trial
O	488	498	randomised
B-total-participants	499	502	235
B-eligibility	503	508	women
I-eligibility	509	513	with
I-eligibility	514	524	metastatic
I-eligibility	525	531	breast
I-eligibility	532	538	cancer
O	539	541	to
O	542	549	receive
O	550	556	either
B-intervention	557	561	high
I-intervention	561	562	-
I-intervention	562	566	dose
I-intervention	567	577	epirubicin
I-intervention	578	581	150
I-intervention	582	584	mg
I-intervention	584	585	/
I-intervention	585	587	m2
I-intervention	588	591	and
I-intervention	592	608	cyclophosphamide
I-intervention	609	613	1500
I-intervention	614	616	mg
I-intervention	616	617	/
I-intervention	617	619	m2
I-intervention	620	624	with
I-intervention	625	635	filgrastim
I-intervention	636	643	support
O	644	649	every
O	650	651	3
O	652	657	weeks
O	658	661	for
O	662	663	3
O	664	670	cycles
O	671	672	(
O	672	676	HDEC
O	676	677	)
O	678	680	or
O	681	689	standard
O	690	694	dose
O	695	705	epirubicin
O	706	708	75
O	709	711	mg
O	711	712	/
O	712	714	m2
O	715	718	and
O	719	735	cyclophosphamide
O	736	739	750
O	740	742	mg
O	742	743	/
O	743	745	m2
O	746	751	every
O	752	753	3
O	754	759	weeks
O	760	763	for
O	764	765	6
O	766	772	cycles
O	773	774	(
B-control	774	778	SDEC
O	778	779	)
O	779	780	.

O	781	788	Primary
O	789	797	outcomes
O	798	802	were
B-outcome-Measure	803	807	time
I-outcome-Measure	808	810	to
I-outcome-Measure	811	822	progression
O	822	823	,
B-outcome-Measure	824	831	overall
I-outcome-Measure	832	840	survival
O	841	844	and
B-outcome-Measure	845	852	quality
I-outcome-Measure	853	855	of
I-outcome-Measure	856	860	life
O	860	861	.

O	862	864	In
B-intervention-participants	865	868	118
O	869	877	patients
O	878	887	allocated
O	888	892	HDEC
O	893	895	90
O	895	896	%
O	897	899	of
O	900	903	the
O	904	911	planned
O	912	916	dose
O	917	920	was
O	921	930	delivered
O	930	931	,
O	932	940	compared
O	941	943	to
O	944	946	96
O	946	947	%
O	948	950	in
O	951	954	the
B-control-participants	955	958	117
O	959	971	participants
O	972	981	allocated
O	982	986	SDEC
O	986	987	.

O	988	993	There
O	994	998	were
O	999	1001	no
O	1002	1013	significant
O	1014	1025	differences
O	1026	1028	in
O	1029	1032	the
B-outcome	1033	1037	time
I-outcome	1038	1040	to
I-outcome	1041	1048	disease
I-outcome	1049	1060	progression
O	1061	1062	(
B-iv-cont-median	1062	1063	5
I-iv-cont-median	1063	1064	.
I-iv-cont-median	1064	1065	7
O	1066	1068	vs
O	1068	1069	.
B-cv-cont-median	1070	1071	5
I-cv-cont-median	1071	1072	.
I-cv-cont-median	1072	1073	8
I-cv-cont-median	1074	1080	months
O	1080	1081	,
O	1082	1083	P
O	1084	1085	=
O	1086	1087	0
O	1087	1088	.
O	1088	1090	19
O	1090	1091	)
O	1092	1094	or
B-outcome	1095	1102	overall
I-outcome	1103	1111	survival
O	1112	1113	(
B-iv-cont-median	1113	1115	14
I-iv-cont-median	1115	1116	.
I-iv-cont-median	1116	1117	5
O	1118	1120	vs
O	1120	1121	.
B-cv-cont-median	1122	1124	16
I-cv-cont-median	1124	1125	.
I-cv-cont-median	1125	1126	5
I-cv-cont-median	1127	1133	months
O	1133	1134	,
O	1135	1136	P
O	1137	1138	=
O	1139	1140	0
O	1140	1141	.
O	1141	1143	29
O	1143	1144	)
O	1145	1152	between
O	1153	1157	HDEC
O	1158	1161	and
O	1162	1166	SDEC
O	1166	1167	,
O	1168	1180	respectively
O	1180	1181	.

O	1182	1190	Patients
O	1191	1193	on
O	1194	1198	HDEC
O	1199	1207	reported
O	1208	1213	worse
B-outcome	1214	1221	quality
I-outcome	1222	1224	of
I-outcome	1225	1229	life
O	1230	1236	during
O	1237	1244	therapy
O	1244	1245	,
O	1246	1249	but
O	1250	1256	scores
O	1257	1265	improved
O	1266	1271	after
O	1272	1282	completion
O	1283	1285	to
O	1286	1297	approximate
O	1298	1303	those
O	1304	1312	reported
O	1313	1315	by
O	1316	1324	patients
O	1325	1334	allocated
O	1335	1339	SDEC
O	1339	1340	.

B-outcome	1341	1350	Objective
I-outcome	1351	1357	tumour
I-outcome	1358	1366	response
O	1367	1370	was
O	1371	1379	recorded
O	1380	1382	in
B-iv-bin-abs	1383	1385	33
O	1386	1387	(
B-iv-bin-percent	1387	1389	28
I-iv-bin-percent	1389	1390	%
O	1390	1391	)
O	1392	1394	on
O	1395	1399	HDEC
O	1400	1403	and
B-cv-bin-abs	1404	1406	42
O	1407	1415	patients
O	1416	1417	(
B-cv-bin-percent	1417	1419	36
I-cv-bin-percent	1419	1420	%
O	1420	1421	)
O	1422	1424	on
O	1425	1429	SDEC
O	1429	1430	.

O	1431	1435	HDEC
O	1436	1444	produced
O	1445	1449	more
B-outcome	1450	1462	haematologic
I-outcome	1463	1471	toxicity
O	1471	1472	.

O	1473	1476	For
O	1477	1482	women
O	1483	1487	with
O	1488	1498	metastatic
O	1499	1505	breast
O	1506	1512	cancer
O	1512	1513	,
B-outcome	1514	1521	disease
I-outcome	1522	1533	progression
O	1533	1534	,
B-outcome	1535	1543	survival
O	1544	1546	or
B-outcome	1547	1554	quality
I-outcome	1555	1557	of
I-outcome	1558	1562	life
O	1563	1567	were
O	1568	1570	no
O	1571	1577	better
O	1578	1582	with
O	1583	1587	high
O	1587	1588	-
O	1588	1592	dose
O	1593	1602	intensity
O	1603	1611	compared
O	1612	1614	to
O	1615	1623	standard
O	1624	1628	dose
O	1629	1631	EC
O	1632	1644	chemotherapy
O	1644	1645	.

B-location	1646	1656	Australian
O	1657	1665	Clinical
O	1666	1672	Trials
O	1673	1681	Registry
O	1682	1694	registration
O	1695	1701	number
O	1702	1721	ACTRN12605000478617
O	1721	1722	.
